✨ Your Portfolio is fetched and updated from zerodha.
Small Chemicals
Market Cap
₹1,781 Cr.
P/E
124.58
About
Tatva Chintan Pharma Chem Limited is a leading specialty chemicals manufacturer in India, producing structure directing agents, phase transfer catalysts, electrolyte salts for super capacitor batterie… Read more
Tatva Chintan Pharma Chem Limited is a leading specialty chemicals manufacturer in India, prod… Read more
Low
621
52W Range
High
1284
  • Tatva Chintan Pharma
  • Paushak
  • Ultramar & Pigments
  • TJI Speciality Chemicals

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

7 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Total reactor capacity (kL)
    • Capacity Utilization - Chemicals - Reactor (%)
    Peer Comparison
    Corporate Actions
    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less
    Customers
    • Asian Paints Ltd.
    • Atul Auto Ltd.
    • Bayer CropScience Ltd.
    • Divi's Laboratories Ltd.
    • Firmenich
    FAQs on Tatva Chintan Pharma Chem Ltd. Business

    Tatva Chintan Pharma Chem Limited is a leading global manufacturer of specialty chemicals like structure directing agents and electrolyte salts for super capacitor batteries, serving industries such as pharmaceuticals and agrochemicals.

    Tatva Chintan Pharma major competitors are Paushak, Ultramar & Pigments, Valiant Organics, 20 Microns, Sadhana Nitro Chem, DMCC Speciality Chem, Chemcon Speciality.
    Market Cap of Tatva Chintan Pharma is ₹1,734 Crs.
    While the median market cap of its peers are ₹822 Crs.

    Tatva Chintan Pharma seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jun Mar Jun Sep Dec Jun Sep Dec
    Investor Presentation Mar Jun Sep Dec Mar Jun Sep Dec Mar Apr Jun Jul Sep Dec Jan Sep Dec
    Conference Call Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Jun Sep Dec
    Conference Call SummaryCon Call Summary
    Discussions & Analysis
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material